[go: up one dir, main page]

BR9712138A - Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition. - Google Patents

Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition.

Info

Publication number
BR9712138A
BR9712138A BR9712138-0A BR9712138A BR9712138A BR 9712138 A BR9712138 A BR 9712138A BR 9712138 A BR9712138 A BR 9712138A BR 9712138 A BR9712138 A BR 9712138A
Authority
BR
Brazil
Prior art keywords
rna virus
isolated
segmented
negative
immunize
Prior art date
Application number
BR9712138-0A
Other languages
Portuguese (pt)
Inventor
Stephen A Udem
Mohinderjit S Sidhu
Joanne M Tatem
Brian R Murphy
Valerie B Randolph
Original Assignee
American Cyanamid Co
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co, Us Health filed Critical American Cyanamid Co
Publication of BR9712138A publication Critical patent/BR9712138A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"VìRUS DE RNA ISOLADO, VACINA, PROCESSO PARA IMUNIZAR UM INDIVìDUO PARA INDUZIR PROTEçãO CONTRA UM VìRUS DE RNA NãO SEGMENTADO, SENTIDO NEGATIVO, DE FILAMENTO úNICO, DA ORDEM MONONEGAVIRALES E PARA PRODUZIR VìRUS DE RNA, MOLéCULA DE áCIDO NUCLEICO ISOLADA E COMPOSIçãO". Vírus de RNA isolado, gerado de modo recombinante, atenuado, não segmentado, sentido negativo, de filamento único, da Ordem Mononegavirales, tendo pelo menos uma mutação atenuante na região de promotor genómico 3' e tendo pelo menos uma mutação atenuante no gene de polimerase de RNA são descritos. As vacinas são formuladas compreendendo estes vírus e um veículo fisiologicamente aceitável. As vacina são usadas para imunização de um indivíduo para induzir proteção contra um vírus de RNA não segmentado, sentido negativo, de filamento único, da Ordem Mononegavirales."ISOLATED RNA VIRUS, VACCINE, PROCESS TO IMMUNIZE AN INDIVIDUAL TO INDUCT PROTECTION AGAINST A NON-SEGMENTED, NEGATIVE, UNIQUE FILMARY, MONONEGAVIRAL ORDER, AND PRODUCTION OF NUCLEA, ROLE AND MOLE VIRUS ISOLATED. Isolated RNA virus, recombinantly generated, attenuated, non-segmented, negative, single-stranded, of the Order Mononegavirales, having at least one attenuating mutation in the 3 'genomic promoter region and having at least one attenuating mutation in the polymerase gene of RNA are described. Vaccines are formulated comprising these viruses and a physiologically acceptable carrier. Vaccines are used to immunize an individual to induce protection against a negative, single-stranded, non-segmented RNA virus of the Order Mononegavirales.

BR9712138-0A 1996-09-27 1997-09-19 Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition. BR9712138A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2682396P 1996-09-27 1996-09-27
PCT/US1997/016718 WO1998013501A2 (en) 1996-09-27 1997-09-19 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales

Publications (1)

Publication Number Publication Date
BR9712138A true BR9712138A (en) 2000-01-18

Family

ID=21833976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712138-0A BR9712138A (en) 1996-09-27 1997-09-19 Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition.

Country Status (8)

Country Link
EP (1) EP0932684A2 (en)
JP (1) JP2000517194A (en)
KR (1) KR20000048628A (en)
CN (1) CN1232504A (en)
AU (1) AU4427897A (en)
BR (1) BR9712138A (en)
CA (1) CA2265554A1 (en)
WO (1) WO1998013501A2 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
CN1273603A (en) * 1997-09-19 2000-11-15 美国氰胺公司 Attenuated respiratory syncytial viruses
JP2002507408A (en) * 1998-03-26 2002-03-12 アメリカン・サイアナミド・カンパニー Mutations responsible for attenuation of measles virus or human respiratory syncytial virus subgroup B
CA2333313C (en) 1998-06-03 2011-11-08 American Cyanamid Company Novel methods for rescue of rna viruses
JP4531255B2 (en) 1998-06-12 2010-08-25 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー Attenuated (-) chain virus with modified interferon antagonistic activity for use as a vaccine and medicament
DE69937999T2 (en) 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag INTERFERON INDUCING GENETICALLY MODIFIED ATTENUATED VIRUSES
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
AU2001257001A1 (en) 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
WO2002000694A2 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Modified morbillivirus v proteins
US7361496B1 (en) 2000-08-02 2008-04-22 Wyeth Rescue of mumps virus from cDNA
WO2002057302A2 (en) 2001-01-19 2002-07-25 Vironovative B.V. A virus causing respiratory tract illness in susceptible mammals
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
MXPA04008088A (en) 2002-02-21 2005-09-30 Medimmune Vaccines Inc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus.
US20050158342A1 (en) 2003-12-23 2005-07-21 Medimmune, Inc. Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1499348B1 (en) 2002-04-26 2014-10-01 MedImmune, LLC Method for producing infectious influenza b virus in cell culture
PT1375512E (en) * 2002-06-20 2009-09-23 Pasteur Institut Infectious cdna of an approved vaccine strain of measles virus. use for immunogenic compositions
DK1375670T3 (en) 2002-06-20 2013-09-23 Pasteur Institut Recombinant measles viruses expressing epitopes of RNA virus antigens and use of the recombinant viruses to prepare vaccine compositions
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
ATE469170T1 (en) * 2003-03-28 2010-06-15 Medimmune Llc COMPOSITIONS AND METHODS USING THE RESPIRATORY SYNCYTIAL VIRUS SUBGROUP B STRAIN 9320
JP2007525178A (en) 2003-04-25 2007-09-06 メッドイミューン バクシーンズ，インコーポレイティド Metapneumovirus strain, its use in vaccine formulations, use as a vector for expression of antigenic sequences, and virus propagation method
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP4980895B2 (en) 2004-05-25 2012-07-18 メディミューン，エルエルシー Influenza hemagglutinin and neuraminidase variants
BRPI0511776B1 (en) 2004-06-01 2016-11-29 Sinai School Medicine genetically engineered swine influenza attenuated virus, immunogenic formulation, pharmaceutical formulation, use of the immunogenic formulation, use of genetically engineered swine influenza attenuated virus, use of the pharmaceutical formulation and method for producing a vaccine, an immunogenic formulation or a pharmaceutical formulation
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
CA2600730C (en) 2005-03-08 2014-11-25 Medimmune, Inc. Influenza hemagglutinin and neuraminidase variants
AU2006262381A1 (en) 2005-06-21 2007-01-04 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
NZ595736A (en) 2005-12-02 2013-05-31 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
DK2016194T3 (en) 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
EP2049662A4 (en) 2006-07-21 2009-12-30 Medimmune Llc Methods and compositions for increasing replication capacity of an influenza virus
CN104140958A (en) 2006-08-09 2014-11-12 米迪缪尼有限公司 Influenza hemagglutinin and neuraminidase variants
US7758868B2 (en) 2006-12-22 2010-07-20 The Penn State Research Foundation Modified polymerases and attenuated viruses and methods of use thereof
JP5666905B2 (en) 2007-06-18 2015-02-12 メディミューン，エルエルシー Influenza B virus having alterations in hemagglutinin polypeptide
EP2318043A4 (en) 2008-07-11 2012-01-25 Medimmune Llc Influenza hemagglutinin and neuraminidase variants
EP2356135B1 (en) 2008-11-05 2017-10-25 Wyeth LLC Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
ES2550179T3 (en) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Chimeric Newcastle disease viruses and uses thereof
SG2014010185A (en) 2009-02-12 2014-06-27 Medimmune Llc Influenza hemagglutinin and neuraminidase variants
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
CA2805505C (en) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
EP2420242A1 (en) 2010-08-20 2012-02-22 Lauer, Ulrich M. Oncolytic measles virus
CN103906843B (en) * 2011-06-08 2016-12-07 维什瓦斯·乔希 Two-plasmid Mammalian Expression System
JP6087908B2 (en) * 2011-06-08 2017-03-08 ジョシ ヴィシュワスＪＯＳＨＩ Ｖｉｓｈｗａｓ A simple two-plasmid mammalian expression system for producing recombinant proteins and viruses
CN108164602A (en) 2011-09-20 2018-06-15 西奈山医学院 Influenza virus vaccine and its application
ES2752190T3 (en) 2012-09-14 2020-04-03 Us Health Brachyury protein, adenoviral vectors encoding Brachyury protein and their use
CN108641002A (en) 2012-12-18 2018-10-12 西奈山伊坎医学院 Influenza virus vaccine and application thereof
EA038981B1 (en) 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Newcastle disease viruses and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP6857498B2 (en) 2014-02-27 2021-04-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Combination method for treating cancer
JP2018504412A (en) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ Influenza virus vaccination regimen
BR112017015789A2 (en) 2015-02-26 2018-03-27 Boehringer Ingelheim Vetmedica Gmbh bivalent swine influenza virus vaccine
JP7048482B2 (en) 2015-08-03 2022-04-05 アメリカ合衆国 Brachyury deletion variants, non-yeast vectors encoding Brachyury deletion variants, and their use
US10973903B2 (en) 2015-08-20 2021-04-13 University Of Rochester NS1 truncated virus for the development of canine influenza vaccines
WO2017031408A1 (en) 2015-08-20 2017-02-23 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
US10478489B2 (en) 2015-08-20 2019-11-19 University Of Rochester Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
US10857224B2 (en) 2016-06-03 2020-12-08 University Of Rochester Equine influenza virus live attenuated vaccines
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
WO2019168911A1 (en) 2018-02-27 2019-09-06 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
MX2021010343A (en) 2019-02-27 2022-01-18 Univ Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses.
US11103576B1 (en) 2020-06-15 2021-08-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Measles virus vaccine expressing SARS-COV-2 protein(s)
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof
TW202529819A (en) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 Tissue specific anellovector delivery
WO2025160409A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations V, Inc. Viral vectors for modulating vegf function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7007491A (en) * 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
JP3045581B2 (en) * 1991-10-14 2000-05-29 社団法人北里研究所 Measles vaccine virus strain identification method
ZA932588B (en) * 1992-04-14 1993-11-02 Sinai School Medicine Genetically engineered attenuated viruses
TW275632B (en) * 1992-04-21 1996-05-11 American Cyanamid Co
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Attenuated respiratory syncytial virus vaccine compositions
DE69532369T3 (en) * 1994-07-18 2010-11-04 Conzelmann, Karl-Klaus, Prof. Dr. Recombinant infectious non-segment shared negative-stranded RNA virus

Also Published As

Publication number Publication date
WO1998013501A3 (en) 1998-08-13
JP2000517194A (en) 2000-12-26
AU4427897A (en) 1998-04-17
CA2265554A1 (en) 1998-04-02
WO1998013501A2 (en) 1998-04-02
EP0932684A2 (en) 1999-08-04
CN1232504A (en) 1999-10-20
KR20000048628A (en) 2000-07-25

Similar Documents

Publication Publication Date Title
BR9712138A (en) Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition.
BR9812232A (en) Human respiratory syncytial virus (rsv) human subgroup b, isolated, recombinantly generated, attenuated, vaccine, process to immunize an individual to induce protection against rsv subgroup b, composition, process to produce attenuated infectious rsv subgroup b, and isolated acid molecule nucleic
ATE138384T1 (en) OLIONUCLEOTIDE ALKYLPHOSPHONATE AND PHOSPHONOTHIOATE
BR0111827A (en) Isolated, recombinantly generated, non-segmented, negative-sense, single-stranded rna virus, genus morbillivirus, immunogenic composition, method for immunizing an individual to induce protection against said virus, method for reducing repression caused by a genus v protein morbillivìrus, isolated nucleotide sequence, composition, and method for producing an infectious morbillivìrus
DE69536039D1 (en) A host cell containing a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
DE69737886D1 (en) INFECTIOUSE RNA VIRUS CLONE, VACCINE, AND THEREFORE DERIVED DIAGNOSTIC ASSAYS
CA2154023A1 (en) Recombinant infectious non-segmented negative strand rna virus
GR3035458T3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
NO874750L (en) Certain DNA sequences derived from a papilloma virus genome, their use in in vitro diagnostics and production of antigenic preparations.
AU6452886A (en) Protection of plants against viral infection
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
KR900700603A (en) Ribozyme
NZ235244A (en) 2'-deoxy-2'-fluoro-ribonucleosides and compositions for the treatment of viral and parasitic diseases
MXPA03000061A (en) Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof.
AP1674A (en) The genome of the HIV-1 inter-subtype (C/B') and use thereof.
EP0507179A3 (en) Equine herpes viruses (ehv) containing foreign dna, process for their preparation and their use as vaccines
BR9815285A (en) Alphaviruses for paramyxoviruses vaccine
ES8608581A1 (en) Synthetic genes for bovine parainfluenza virus
BR9707400A (en) Vaccines against gene 63 product of varicella zoster virus.
PT87004A (en) PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS AND COMPOSITES 3'-AZIDE-2 ', 3'-DIDESOXY-IN OSINE AND 3'-FLUORO-2', 3'-DIDESOXYGUANOSINE
BR9610932A (en) Process for storing microorganisms, microorganism composition and use
WO1999057284A3 (en) Attenuated influenza viruses
Kaper et al. Cucumber mosaic virus-associated RNA 5 V. Extensive nucleotide sequence homology among CARNA 5 preparations of different CMV strains
CA2258675A1 (en) 2-cyclopenten-1-one as an inducer of hsp70
ES2132330T3 (en) VACCINE FOR THE PROTECTION OF HORSES AGAINST INFECTION WITH THE EQUINE HERPES VIRUS.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO, DE ACORDO COM ARTIGO 8O DA LPI